XML 60 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Marketable Securities and Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial assets and liabilities measured at fair value on a recurring basis
The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2013:
 
 
Fair Value Measurements at
 
September 30, 2013
 
Total
 
Using Quoted Prices
in Active Markets
for Identical Assets
(Level 1)
 
Using Significant
Other Unobservable
Inputs
(Level 2)
 
Using Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
18,338,897

 
$
18,338,897

 
$

 
$

Mutual funds
13,104,863

 

 
13,104,863

 

Investment in affiliated entity
11,084,123

 
11,084,123

 

 

Common stock warrants
244,900

 

 

 
244,900

Total Assets
$
42,772,783

 
$
29,423,020

 
$
13,104,863

 
$
244,900

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
14,095,818

 
$

 
$

 
$
14,095,818

Total Liabilities
$
14,095,818

 
$

 
$

 
$
14,095,818


The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2012:
 
 
Fair Value Measurements at
 
December 31, 2012
 
Total
 
Using Quoted Prices
in Active Markets
for Identical Assets
(Level 1)
 
Using Significant
Other Unobservable
Inputs
(Level 2)
 
Using Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
1,686,406

 
$
1,686,406

 
$

 
$

Mutual funds
7,583,931

 

 
7,583,931

 

Certificates of deposit
250,000

 

 
250,000

 

Municipal bonds
200,070

 

 
200,070

 

Investment in affiliated entity
10,703,332

 
10,703,332

 

 

Common stock warrants
267,200

 

 

 
267,200

Total Assets
$
20,690,939

 
$
12,389,738

 
$
8,034,001

 
$
267,200

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
2,859,899

 
$

 
$

 
$
2,859,899

Total Liabilities
$
2,859,899

 
$

 
$

 
$
2,859,899

Assumptions used to estimate the fair values of the common stock warrants
The range of assumptions used to estimate the fair values of common stock warrants at September 30, 2013 are presented below:
 
Risk-free interest rate
0.13%-1.52%
Expected volatility
88%-119%
Expected life in years
0.75-4.96
Dividend yield
Change in fair value of the financial assets
The following table presents a summary of changes in fair value of the Company’s total Level 3 financial assets for the nine months ended September 30, 2013:
Balance at January 1, 2013
$
267,200

Decrease in fair value included in change in fair value of common stock warrants
(22,300
)
Balance at September 30, 2013
$
244,900


Changes in fair value of the financial liabilities
The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the nine months ended September 30, 2013:
 
Balance at January 1, 2013
$
2,859,899

       Record fair value of warrants issued in March 2013 financing
5,968,244

Increase in fair value included in change in fair value of common stock warrants
39,557,404

Change in classification from liability to stockholders' equity due to warrant exercises
(34,289,729
)
Balance at September 30, 2013
$
14,095,818

OncoSec [Member]
 
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair values of the OncoSec common stock warrants at September 30, 2013 are presented below:

Risk-free interest rate
0.63%
Expected volatility
85%
Expected life in years
3-3.5
Dividend yield